Personalis Inc Stock
Price
Target price
€1.16
€1.16
-5.570%
-0.068
-5.570%
€3.23
25.04.24 / Tradegate
WKN: A2PLTK / Symbol: PSNL / Name: Personalis / Stock / Biotechnology & Medical Research / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Personalis Inc Stock
Heavy losses for Personalis Inc today as the stock fell by -€0.068 (-5.570%).
Currently there is a rather positive sentiment for Personalis Inc with 5 Buy predictions and 0 Sell predictions.
Based on the current price of 1.16 € the target price of 3 € shows a potential of 158.4% for Personalis Inc which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Personalis Inc stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Personalis Inc in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
B****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Personalis Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Personalis Inc | -5.570% | 0.869% | -12.377% | -45.442% | -44.183% | -93.941% | - |
| Stoke Therapeutics Inc | -8.850% | -3.636% | - | - | - | - | - |
| Immuron | -3.570% | -0.917% | -9.244% | 23.429% | 29.341% | -49.296% | - |
Comments
Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $3.50 price target on the stock.
Show more
Ratings data for PSNL provided by MarketBeat
Personalis, Inc. (NASDAQ: PSNL) had its price target raised by analysts at Needham & Company LLC from $2.30 to $3.50. They now have a "buy" rating on the stock.
Show more
Ratings data for PSNL provided by MarketBeat
Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.30 price target on the stock.
Show more
Ratings data for PSNL provided by MarketBeat
News
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal®
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive